Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo.
Trince has raised $6.1M in total funding. The most recent round was Undisclosed. The last funding was announced in January 2026.
Trince's investors include Novalis Biotechnology Incubation, Qbic Fund.
Trince is headquartered in Asse, Belgium.
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo.
Trince is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trince — Funding & Investors." VCBacked, January 20, 2026, https://www.vcbacked.co/company/trince. Accessed September 30, 2026.
VCBacked. (2026). Trince — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/trince
{{cite web |title=Trince — Funding & Investors |url=https://www.vcbacked.co/company/trince |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated